GlobeNewswire

Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
04/11/2026
Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at [...]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today [...]
electroCore Announces Third Quarter 2026 Financial Results
04/11/2026
Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from [...]
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
04/11/2026
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND- [...]
Pennant Reports Third Quarter 2026 Results
04/11/2026
Conference Call and Webcast scheduled for tomorrow, November 5, 2026 at 10:00 am MT EAGLE, Idaho, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
04/11/2026
Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q [...]
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026
04/11/2026
Company highlights to include strategy for entering CD228V Co-development and Licensing Agreement and Proposed SkinJect® Business Combination and Concurrent Financing LOI PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- [...]
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
04/11/2026
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at [...]
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]
Clover Health Reports Third Quarter 2026 Results
04/11/2026
Business Highlights: Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth Improved Full Year 2026 guidance across all [...]
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 [...]
PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
04/11/2026
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
04/11/2026
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
04/11/2026
– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant [...]
Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
PacBio Announces Third Quarter 2026 Financial Results
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026. Recent Business Highlights Delivered total revenue of $40.6 million [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum